Abstract: It is well established that cholera toxin (CT) produced by Vibrio cholerae acts as a potent mucosal adjuvant; however, the native form of this molecule causes severe diarrhea. Furthermore, both native CT and its B-subunit derivative bind to monosialogangliosides (GM1) in membrane raft microdomains on neural tissues and are thus unsuitable for use in humans. In this study, we evaluated the adjuvanticity of the CT A-subunit (CT-A) administered with ovalbumin (OVA) by the nasal route. We found that nasal administration of OVA plus CT-A elicited both mucosal and systemic antibody (Ab) responses. Immunization of mice with OVA plus CT-A resulted in the induction of OVA-specific IgA Abs in saliva and nasal secretions. Furthermore, significant OVA-specific serum immunoglobulin (Ig) G and IgA Ab responses were induced. Antibody-forming cell (AFC) analysis confirmed the Ab titer findings by revealing significant numbers of OVA-specific IgA AFCs in submandibular glands. In addition, splenic lymphocytes restimulated with OVA in vitro exhibited significant proliferative responses. Thus, CT-A might be a candidate for an effective adjuvant for inducing antigen (Ag)-specific Ab responses in human systemic and mucosal compartments, such as the oral cavity. (J. Oral Sci. 45, 25-31, 2003) 
Introduction
Cholera toxin (CT) consists of an enzymatically active A-subunit that catalyzes adenosine diphosphate (ADP)-ribosylation of the Gsla protein. The B -subunits of CT (CT-B) bind to monosialoganglioside (GM1) (1) (Fig. 1) . The binding of CT to intestinal epithelial cells induces a cascade of events that ultimately results in secretion of chloride and water with subsequent diarrhea (1, 2) . CT is a mucosal adjuvant and when given with protein vaccines by the oral or nasal route it induces mucosal and systemic immunity (3) (4) (5) (6) (7) (8) . Furthermore, mutants of CT (9,10) have been shown to be devoid of toxicity but to retain full mucosal adjuvanticity when given by the nasal route.
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Fax: +81-47-360-9335 E-mail: ottis@mac.com antigen-presenting cells (APCs) (11-13). CT-B, however, failed to stimulate APC co-stimulatory molecule expression (8). In addition, studies have shown that CT-B does not enhance immune responses to mucosally co-administered protein antigens (Ags) (10, 13, 14) . However, some workers observed that CT-B enhanced soluble peptide presentation by peritoneal macrophages in vitro (15) and CT-Bpretreated B-cell hybridomas enhanced interleukin (IL)-4 production by Th2 cell lines after stimulation (16) . CT binds to GM1 on epithelial cells via CT-B and requires endocytosis followed by transport across the epithelial cell to reach the basolateral membrane where it induces water and chloride secretion resulting in the characteristic cholera-type diarrhea (1). GM1 is also expressed abundantly in the central nervous system (CNS) and, after administration to mice by the intranasal route, both CT and CT-B have been shown to accumulate in the main olfactory nerves and epithelium (ON/E) and olfactory bulbs (OB s) (18) . Furthermore, GM1-mediated transport is responsible for this accumulation of CT-B and CT in the OBs. Thus, following intranasal delivery, CT or CT-B targets the ON/E and OBs, which raises the important possibility of neuronal damage with the intranasal use of these proteins in humans.
In order to eliminate the binding of CT-B to GM1 with subsequent neuronal damage when CT is given nasally , we have evaluated the adjuvant activity of nasally administered CT A-subunit (CT-A). The results obtained in this study suggest that nasal administration of CT-A would be an effective adjuvant for the induction of Agspecific mucosal and serum antibody (Ab) responses to co-administered proteins.
Materials
and Methods Mice BALB/c mice were purchased from Charles River Japan and maintained under pathogen-free conditions in the experimental room of Nihon University School of Dentistry at Matsudo. All mice were provided with sterile food and water ad libitum and were used in this study when they were 8-12 weeks of age.
Antigen and adjuvants
Chicken egg ovalbumin (OVA; grade V) was purchased from Sigma Chemical Co. (St. Louis , MO). CT-A and CT were purchased from List Biologic Laboratories (Campbell , CA).
Immunization and sample collection
Mice were immunized nasally on days 0 , 7, and 14 with a 10-pl aliquot (5 pl per nostril) of phosphate-buffered saline (PBS) containing 100 pg OVA alone or combined with 500 ng of CT-A or CT. Serum, saliva and nasal wash samples were collected from each group, as described elsewhere (2-5,8), on day 21 to examine Ag-specific Ab responses.
Detection of Ag-specific
Ab isotype responses The serum, saliva and nasal wash sample Ab titers were determined by enzyme-kinked immunosorbent assay (ELISA) as described elsewhere (2) (3) (4) (5) 8) . The assay was conducted using Falcon Microtest III assay plates (Becton Dickinson, Oxford, CA), which were coated with OVA (1 mg/ml), incubated overnight at 4°C in a humid atmosphere, washed with PBS and blocked with PBS containing 1% w/v bovine serum albumin. After washing with PBS, serially diluted serum, saliva or nasal wash samples were added, in duplicate, to the wells. Following 4 hours of incubation at room temperature, the plates were washed with PBS containing 0.05% v/v Tween 20 and horseradish peroxidase-labeled goat anti-mouse p, y or a heavy chainspecific Abs (Southern Biotechnology Associates, Birmingham, AL) were added to the appropriate wells. The plates were incubated at room temperature for 4 hours, washed with PBS and developed with 1.1 mM of 2,2' -azino-bis (3-ethylbenz-thiazoline-6-sulfonic acid) in 0 .1 M citrate-phosphate buffer containing 0 .01 % v/v H202 (Moss, Inc., Pasadena, MA) for 15 minutes at room temperature. IgG subclass analysis was carried out using horseradish peroxidase-labeled goat anti-mouse yl, y2a , Associates) exactly as described above for the anti-heavy chain-specific analysis. End-point titers were expressed as the reciprocal log2 of the highest dilution , which gave an optical density in a plate reader at 414 nm (model Biolumin 960; Molecular Dynamics) that was 0.1 units greater than the background level after incubation for 15 min .
ELISPOT for assessment of the numbers of Abforming cells (AFCs)
Single cell suspensions were obtained from the spleens (SPs) and salivary glands (SGs) of nasally-immunized mice, as described previously (2-5). The mononuclear cells were obtained at the interface of the 40% and 75% layers of a discontinuous Percoll gradient (Amersham Pharmacia Biotech, Piscataway, NJ). To determine the numbers of Ag-specific AFCs, an ELISPOT assay was performed , as described previously (2) (3) (4) (5) In the initial experiment, we examined whether nasal administration of OVA plus CT-A as a mucosal adjuvant could induce OVA-specific Ab responses. Nasal immunization of mice with OVA plus CT induced significant OVA-specific serum IgG, IgA and IgM Ab titers when compared with mice given OVA alone. Further, those serum Ab responses were comparable to those induced by nasally administered OVA plus CT (Fig. 2) . As expected, administration of CT-A or CT alone did not induce OVA-specific Ab responses that were above the dilution cut-off level (Log2 of 7) . Analysis of the IgG subclass responses of mice given OVA plus CT-A or CT revealed that the major subclasses were IgG1 and IgG2b (Fig. 3) .
As CT given nasally has been shown to be an effective adjuvant for the induction of Ag-specific mucosal IgA Abs against co-administered proteins (3-5,8), it was important to determine whether OVA-specific IgA Ab responses were induced in mucosal secretions when CT-A was given with OVA. Our results showed that nasal administration of OVA plus CT-A induced significant levels of OVAspecific mucosal IgA Ab responses in saliva and nasal wash samples when compared with those induced by OVA alone (Fig. 4A saliva, and 4B nasal secretions). As expected, nasal delivery of CT-A or CT alone failed to induce OVAspecific Ab titers greater than log2 of 3 (data not shown). (Table 1) . Furthermore, analysis of B cells producing OVA-specific Abs supported the presence of increased titers of serum Abs. Thus, significant numbers of OVA-specific IgG and IgA AFCs were found in the SPs of mice immunized nasally with OVA plus CT-A or CT when compared with mice given OVA alone (Table 1) . These findings further demonstrated that CT-A acted as an adjuvant for the induction of Ag-specific Ab responses in both mucosal and systemic compartments.
Analysis of OVA-specific T cell responses As nasal immunization with OVA plus CT-A induced OVA-specific Ab responses, it was important to examine the Ag-specific T-cell responses.
When splenic mononuclear cells from SP of mice immunized with OVA plus CT-A were restimulated with OVA in vitro, the levels of the proliferative responses induced were identical to those seen with splenocytes from mice immunized with OVA plus CT (Fig. 5) . Splenocytes from mice given OVA alone showed essentially no increased proliferation (Fig . 5) . These results indicate that CT-A, like CT, was an effective adjuvant for the induction of Ag-specific T-cell proliferative responses to a co-administered protein Ag .
Discussion
In the present study, we assessed the potential of CT-A to induce a mucosal IgA response to a co-administered protein Ag. Our results showed that nasal administration of OVA plus CT-A as a mucosal adjuvant induced significant OVA-specific IgG, IgA and IgM Ab responses in serum and IgA Ab responses in mucosal secretions. Furthermore, splenocytes from mice given OVA plus CT-A exhibited significant OVA-specific proliferative responses. These findings indicate that CT-A is an effective adjuvant for the induction of Ag-specific Ab responses in both systemic and mucosal compartments when given by a mucosal route, such as the intranasal one.
CT has been widely used as an adjuvant for mucosal immunization (3, 5, (19) (20) (21) (22) (23) (24) . In this study, we also found that nasal administration of CT acted as an adjuvant to OVA and induced OVA-specific mucosal IgA, as well as serum IgG, IgA and IgM, Ab responses. However, despite these beneficial attributes, CT is unsuitable for use in humans because the ADP-ribosyltransferase activity of CT-A causes severe diarrhea (1, 25) . Thus, a number of groups have assessed the adjuvant effects of CT-B and found that CT-B enhances soluble peptide presentation by peritoneal macrophages in vitro (16) . Furthermore, CT-B-pretreated B-cell hybridomas enhanced IL-4 production by Th2 cell lines after stimulation with either an Ag or an anti-CD3 monoclonal Ab (15) , suggesting that CT-B may have some adjuvant properties. However, CT-B does not appear to be as effective as CT for induction of immune responses (17) . These studies suggest that CT-B acts mainly as a (18) and preincubating either molecule with its ligand GM1 before intranasal application inhibited accumulation of CT-B and CT in the OB. In mammals, the sense of smell is controlled by the ON/E, which is directly connected to the OBs as the first neural integrative center and to the olfactory cortex as the second integrative center (18, 26, 27) . The neuronal connections between the ON/E and the OBs are used by pathogens to enter the CNS. These findings imply that following intranasal application, CT-B targets the ON/E and OB, which raises the important possibility of neuronal damage with the intranasal use of these proteins in humans. Thus, in this study, in order to eliminate the binding of CT-B to the GM1 receptor, CT-A was administered nasally with a protein Ag. The results presented above demonstrate that nasal administration of OVA plus CT-A as an adjuvant elicited OVA-specific Ab responses in both the serum and mucosal secretions. However, it is interesting to note that OVA-specific salivary IgA Ab titers in mice given OVA plus CT-A were lower than those seen in mice given OVA plus CT, despite the numbers of anti-OVA AFCs in the salivary glands of both groups of mice being identical. A possible explanation is that the amounts of Abs secreted by each AFC in the salivary glands of mice given OVA plus CT-A may have been lower than those in mice given OVA plus CT. Thus, the adjuvant activity of CT-A in mucosal lymphoid tissues may vary and certain mucosal tissues, such as salivary glands, may be less sensitive to CT-A than to CT. Studies are underway to elucidate the reason(s) for this difference. Taken together, these results suggest that CT-A alone is an effective adjuvant for nasal immunization and that binding of CT-B to GM1 is not required for the adjuvant effect of CT. However, it should be noted that the CT-A used in this study was purified from Vibrio cholerae and therefore, may have been contaminated with a trace amount of CT-B. If it was, then the residual CT-B may have contributed to the adjuvanticity of CT-A. We are currently generating recombinant CT-A to eliminate CT-B contamination for use in a future immunization study.
Our results showed that CT-A was an effective adjuvant and, when given nasally, it elicited mucosal and systemic Ab responses to a co-administered protein Ag. Importantly, however, it is well established that CT-A accounts for the clinical manifestations of cholera, and is thus unsuitable for use in humans. CT-A binds to nicotinamide adenosine diphosphate and catalyzes ADP-ribosylation of Gs a. This guanosine triphosphate (GTP)-binding protein activates adenyl cyclase with subsequent elevation of cyclic adenosine monophosphate (cAMP) levels, which in epithelial cells results in secretion of water and chloride ions into the small intestine (1). Thus, in order to develop an adjuvant suitable for use in humans, the ADPribosyltransferase activity of CT-A must be eliminated. Several groups have reported that single amino acid substitution mutants of the heat-labile enterotoxin of enterotoxigenic Escherichia coli (R7K, S63K and R192G) lack ADP-ribosyltransferase activity yet retain their adjuvant properties (29) (30) (31) . Other studies have also shown that mutating CT by substituting a single amino acid in the ADP-ribosyltransferase active center rendered two mutants of CT (S61F and El 12K) enzymatically inactive and thus non-toxic; however, these mutant CTs still supported Ag-specific immune responses when administered parenterally (3,9,10). These studies provide evidence that ADP-ribosyltransferase activity is not required for adjuvant activity of CT and, together with our findings, suggest that nasal administration of genetically manipulated non-toxic mutant CT-A as a mucosal adjuvant could be a practical regimen for use in humans.
